PUBLIC COMPANY
save$PRAXPraxis Precision Medicines, Inc.
$PRAX379.60+3.49%Boston, MA, USupdated 43m ago
community read0 votes
pipeline
3
marketed
0
phase 3
1
catalysts ytd
2
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 32pre_registration
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →🐶 Hiring Signal
News
- Sarepta's FDA decision date; Flare gets Anna Protopapas as CEOPlus news about Deerfield, InflaRx, Praxis, Nuvectis, Pyxis Oncology, Vistagen, Arcutis Biotherapeutics and Nxera. 🔎 FDA to decide on future of Sarepta exon-skipping drugs by end of February: The…endpoints · 1mo ago
- Praxis sinks on late-stage study fail for seizure pill, halts second trialPraxis Precision Medicines has had a decent run over the past eight months or so, with two major clinical wins. But on Monday, the company disclosed a late-stage failure for its investigational sei…endpoints · 2mo ago
Data sources
last refreshed 17m ago
Found something off?
comments(0)
5-min edit window · permanent after that